Acadia drug approval could clear way for Axovant dementia therapy

April 28 (Reuters) - An imminent ruling on Acadia Pharmaceuticals Inc's drug for Parkinson's disease psychosis is being closely watched by a Bermuda-based company with a similar treatment for dementia.